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ABSTRACT
The development of technologies that allow the
stable delivery of large genomic DNA fragments in
mammalian systems is important for genetic studies
as well as for applications in gene therapy. DNA
transposons have emerged as flexible and efficient
molecular vehicles to mediate stable cargo transfer.
However, the ability to carry DNA fragments >10 kb
is limited in most DNA transposons. Here, we show
that the DNA transposon piggyBac can mobilize
100-kb DNA fragments in mouse embryonic stem
(ES) cells, making it the only known transposon
with such a large cargo capacity. The integrity of
the cargo is maintained during transposition, the
copy number can be controlled and the inserted
giant transposons express the genomic cargo.
Furthermore, these 100-kb transposons can also
be excised from the genome without leaving a foot-
print. The development of piggyBac as a large cargo
vector will facilitate a wider range of genetic and
genomic applications.
INTRODUCTION
Genomic sequences contain not only protein-coding
regions, but also important regulatory elements, which
are critical for appropriate gene expression levels as well
as regulated spatial–temporal expression in an organism.
Although heterologous promoter-driven cDNA sequences
can be readily introduced as transgenic elements, these
rarely provide the full repertoire of alternative isoforms,
physiological-relevant expression patterns and are prone
to silencing. Therefore, the delivery of large contiguous
genomic sequences is essential to achieve regulated gene
expression. Episomal vectors based on Epstein–Barr virus
(1) and Herpes Simplex Virus type 1 (2), have been used to
introduce large genomic sequences into mammalian cells.
As episomes can be lost without selection pressure, they
do not guarantee indefinite expression of the delivered
cargo. Long-term expression of a transgene is most
reliably achieved by stable integration. Retroviral and
lentiviral vectors have been used for this purpose, but
their cargo capacity is limited to 10 kb and they are not
suited for the delivery of intron-containing cargos.
Additionally, these viral systems have immunogenic and
tumorigenic potential.
Transfection of naked DNA has been used for delivery
of large transgenes. Pronuclear injection of bacterial arti-
ficial chromosomes (BACs) has been achieved for trans-
genes of up to 300 kb (3). However, the integrity,
integration site and copy number of the delivered
genomic fragments can not be controlled. BAC vectors
have also been used for targeting large cargos to defined
genomic positions in ES cells via homologous recombin-
ation (4), but the efficiency is locus dependent and can be
very low. Site-specific recombinases such as Cre have also
been used to deliver BACs to a pre-defined genomic
location by recombination-mediated cassette exchange
(5,6); however, pre-engineering of target sites in the
genome is necessary. While these methods are useful for
certain applications, all have limitations and none enables
the revertible insertion of large DNA fragments.
DNA transposable elements are DNA segments that
can mobilize in a host genome. Mobilization is catalyzed
by a transposase enzyme which recognizes the inverted
terminal repeats (ITRs) of the transposon, and ‘cuts’ the
DNA segment from where it resides and ‘pastes’ it into a
new location. These unique properties have been exploited
extensively to deliver DNA fragments in a wide range of
model organisms. The use of DNA transposons in mam-
malian genomes was hampered for many years by the lack
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of active elements. The re-activation of the DNA trans-
poson named Sleeping Beautymarked the beginning of the
development of transposon technologies for use in
complex mammalian genomes (7). The repertoire of trans-
posons that can be used in mammalian genomes has been
extended recently by the discovery and development of
several other elements from different transposon families
(8–10). piggyBac (PB), originally isolated from the
cabbage looper moth Trichoplusia ni (11), has been
shown to efficiently transpose in both insect and mamma-
lian genomes. Among all the known DNA transposons,
PB has the unique ability to transpose with a relatively
large cargo and excise without leaving any footprint (8).
Transposition of PB with cargos up to 14.3 kb has been
demonstrated in mice without a significant loss of trans-
position efficiency (8). Sleeping Beauty, on the other hand,
exhibits a diminished transposition activity when the
cargo size approaches 10 kb (12). Utilizing its capacity
and the feature of seamless removal, PB vectors have
been developed as an efficient tool to generate factor
free-induced pluripotent stem (iPS) cells (13–15).
However, the full extent of PB’s capacity for delivery
and removal of large DNA fragments from mammalian
genomes has not been investigated, despite the advantages
that high cargo-capacity transposons can bring to genome
engineering and gene therapy.
MATERIAL AND METHODS
Plasmids and BAC constructions
The human hypoxanthine phosphoribosyltransferase 1
(HPRT) containing BAC (RP11-674A04) and
fumarylacetoacetate hydrolase (FAH) containing BAC
(RP11-2E17) were obtained from the Wellcome Trust
Sanger Institute BAC clone Archives. The loxP site on
the backbone of both BACs was replaced by the
EM7-Zeocin resistant cassette (gift from Junji Takeda at
Osaka University) by recombineering (16). The plasmid
containing both PB ITRs was a gift from Xiaozhong
Wang at Northwestern University. PL451, PL452 and
PL313 are gifts from Pentao Liu at Wellcome Trust
Sanger Institute. The PB5’ITR was amplified by the
polymerase chain reaction (PCR) using primers
Neo-PB5-F and Neo-PB5-R and the BamHI/SacII
digested PCR fragment was inserted downstream of a
loxP-flanked PGK-EM7-Neo cassette in PL452, giving
rise to pNeoPB5. The PB3’ITR was PCR-amplified with
primers Bsd-PB3-F and Bsd-PB3-R and the NotI/
SacII-digested PCR fragment was inserted downstream
of an EM7-Blasticidin (Bsd) cassette in PL313, giving
rise to pBsdPB3. The SalI/MluI-digested PCR fragment
of EM7-Bsd cassette and the MluI/NotI-digested PCR
fragment of the Cytomegalovirus (CMV) promoter was
ligated into SalI/NotI-digested pBsdPB3, to give rise to
pML114. The PacI/PciI-digested PCR fragment of
Puro-pA was ligated into pNeoPB5 to give rise to
pML118. To construct the PB-HPRT BAC series, the
PB50ITR together with the loxP-flanked PGK-EM7-Neo
cassette was PCR amplified with 110 bp chimeric PCR
primers (PB3-forward and PB3-reverse) and inserted
10-kb downstream of the HPRT stop codon on the
HPRT BAC by recombineering. The loxP-flanked
Neomycin cassette was excised by L-arabinose-induced
Cre expression in the bacterial strain EL350 (16).
PGK-PuroDtk was cloned from YTC37 (17) into PL451.
A second round of recombineering was carried out to
introduce a PCR-amplified PGK-PuroDTK/Frt-PGK-
EM7-Neo-Frt fragment (using chimeric primers ML157f
and ML157r) immediately downstream of the PB50ITR on
the BAC. The PGK-EM7-Neo cassette was removed by L-
arabinose induction in the EL250 strain (16). The
EM7-Bsd-PB30ITR fragment was inserted either 10- or
40-kb upstream of the HPRT start codon to generate
PB transposons, PB-HPRT-70 and PB-HPRT-100, with
cargos of 70 kb (using primers 70 kb-F and 70 kb-R) and
100 kb (using chimeric primers ML160f and ML160r), re-
spectively. To construct the 28-kb PB vector,
PB-HPRT-28, a plasmid made by PCR cloning (using
primers ML162fx and ML162r) of a loxP-flanked
PGK-EM7-Neo cassette was inserted 30 of the human
HPRT mini-gene (18). The DNA fragment excised from
this plasmid containing exons 3–9-portion of the hHPRT
mini-gene together with the loxP-flanked PGK-EM7-Neo
cassette was used to replace the genomic region of exons
3–9 in PB-HPRT-70 by recombineering.
To construct the PB-FAH-62.5 BAC, a PCR fragment
(amplified using chimeric primers ML280F and ML280R
and pML114 as the template) containing EM7-Bsd-
CMV-PB3 was inserted 11-kb upstream of the FAH
start codon using recombineering. Approximately 300 bp
mini-homology arms were PCR cloned into pML118
(primers ML282F/ML282R and ML283F/ML283R).
The DNA fragment containing PB5-Puro-pA and the
mini-homology arms was subsequently released by MfeI/
NotI digestion, and the fragment was inserted 17-kb
downstream of the FAH stop codon by recombineering.
The sequences of all primers in this section are shown in
Supplementary Table S1. A PGK-Puromycin resistant
cassette, the EcoRI/NotI fragment from plasmid
pPGKPuro (17), was blunt ligated to NaeI/SapI-digested
plasmids CMV-mPBase (19) or CMV-HyPBase (20), to
give rise to CMV-mPBase-PGK-Puro and CMV-
hyPBase-PGK-Puro. The control plasmid CAG-
eGFP-bGHpA contains the PGK-PuroDtk cassette.
ES cell culture, transfection and selection
Mouse AB2.2 ES cells were cultured on a monolayer
of g-irradiated SNLP76/7 feeder cells at 37C in a
humidified incubator with 5% CO2 as previously
described (21). The ES cell culture medium (M15)
consists of knockout DMEM, 15% fetal calf serum,
0.1mM b-mercaptoethanol, 2mM L-glutamine, 50U/ml
penicillin and 39 mg/ml streptomycin. Prior to genomic
DNA extraction, ES cells were passaged to either
96-well or 24-well gelatinized plates. The cells were lyzed
with sarcosyl containing lysis buffer (2.5 g sarcosyl per
500ml buffer, 10mM Tris–HCl, 10mM EDTA, 10mM
NaCl) supplemented with Proteinase K (1mg/ml) at
55C overnight. DNA was extracted using ethanol precipi-
tation. Transient transfection of mPBase and hyPBase was
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achieved with Lipofectamine 2000 (Invitrogen) using
3 106 cells and 24 mg of PBase or control plasmids
(CMV-hyPBase-PGK-Puro, CMV-mPBase-PGK-Puro
or CAG-eGFP-bGHpA-PGK-Puro). Enrichment of
PBase expressing cells was achieved by a 48-h pulse selec-
tion of 1 mg/ml puromycin starting 16-h post lipofection.
The transfection efficiency was determined by fluorescent-
activated cell sorting (FACs) analysis to quantify the
fraction of eGFP expressing cells post-CAG-eGFP-
bGHpA transfection. The integrity of purified BACs was
verified prior to electroporation by pulse field gel electro-
phoresis (Supplementary Figure S1). BAC electroporation
was conducted using 1 107 ES cells electroporated with
5 mg of BAC DNA and plated on a 90mm culture dish
72-h post lipofection. After 3 days in M15, the cells were
trypsinized and one-eighth of the cells were replated in a
fresh 90mm plate. Drug selection was initiated the follow-
ing day. Drugs and their final concentrations used: HAT
(100 mM hypoxanthine, 400 nM aminopterin and 16 mM
thymidine), 200 nM FIAU (1-(2-Deoxy-2-fluoro-b-D-
arabinofuranosyl)-5-iodouracil), 180 mg/ml G418 and
1 mg/ml puromycin. When HAT selection was used, cells
were recovered in HT (100mM hypoxanthine and 16 mM
thymidine) medium for an additional 2 days. For PB
excision analysis, clones that were positive for
PB-mediated integration were used. A total of 5 105
cells were transfected with 4 mg CMV-hyPBase-
PGK-Puro plasmid or control plasmid CAG-eGFP-
bGHpA using Lipofectamine 2000 followed by a pulse
puromycin (1 mg/ml) selection. Three days post
lipofection, 1 105 ES cells were plated in a 90mm plate
and selected with 10 mM 6-TG for 8 days. The resulting
colonies were counted and expanded for further molecular
analysis. The primers used for genomic PCRs are shown in
Supplementary Table S2.
Southern blotting
Genomic DNA was extracted and digested with XbaI and
SpeI, size-fractionated on a 0.8% agarose gel and
transferred to Hybond blotting membrane (Amersham)
using standard alkaline transfer methods. The probe
used was a 273 bp PB50ITR fragment, isolated from
EcoRI/NsiI digestion of pNeoPB5. Southern blot hybrid-
ization was conducted as described previously (21).
Splinkerette PCR
The splinkerette-PCR method has been described previ-
ously (22). Briefly, Sau3AI-digested genomic DNA was
ligated with a splinkerette linker. The linker was made
by annealing oligos HMSpAa and HMSpBb. The
ligation mixture was used as a template for the nested
PCR. Sau3AI does not digest the PB ITRs, thus the PB
ITR-genomic junction fragment can be PCR amplified
using a PB ITR-specific primer and a linker-specific
primer. In the first round, primers PB3-1 and HMSp1
were used to amplify the PB30ITR-genomic junction and
PB5-1 and HMSp1 to amplify PB50ITR-genomic junction.
In the nested PCR, PB3-2 and HMSp2 were used to
amplify the PB30ITR-genomic junction and PB5-2 and
HMSp2 to amplify the PB50ITR-genomic junction.
Primers PB3-seq and PB5-seq were used for sequencing
the PCR products generated from PB30ITR and
PB50ITR, respectively. The primer sequences in this
section are shown in Supplementary Table S3.
Regional high-density CGH array
The 230-kb human genomic region ChrX: 133 358 379–
133 591 045 (hg18), covering the whole BAC
(RP11-674A04) was used to design the hybridization
probes for an Agilent regional CGH array (8 15 K),
with the criteria that the probes must pass a similarity
score filter to exclude probes with secondary genomic
alignments and exclusion of repetitive genomic regions.
Additional criteria were adopted to avoid mouse–human
cross species hybridization. The rules were: (i) reject
probes that have >90% identity to the mouse genome;
(ii) reject probes which have 20 bp or more of uninterrupt-
ed sequence match to the mouse genome. In total, 1773
probes were selected from this region to provide an
average detection resolution of 130 bp, and they were
printed in triplicate on the array. The remaining 9600
probes were a random selection of probes from Agilent
catalogue mouse CGH HD probes to provide the base-
line normalization. The array data (E-MEXP-2788) was
deposited at ArrayExpress (http://www.ebi.ac.uk/
arrayexpress/). The ES-cell genomic DNA was extracted
using Puregene kit (Qiagen). The extracted DNA with the
large-cargo PB integrated was compared to the DNA
extracted from parental AB2.2. Both samples and the
control were mixed in equal amounts with pooled
genomic DNA from human male primary cell lines. In
this array, within the high-density human probe region,
the copy number increase of one on the Log2 scale repre-
sents the gain of an extra copy. The raw array data was
normalized using a robust cubic spline interpolation
method contained inside the R package aCGH. Spline
(http://cran.r-project.org/web/packages/aCGH.Spline/
index.html) to adjust for dye biases. A custom wavelet
transform was applied to remove the presence of
genomic waves and the true baseline was estimated using
the median value reported by the 9600 randomly selected
probes.
Illumina sequencing and analysis
The outline of the Illumina sequencing and analysis
pipeline is shown in Supplementary Figure S2 and the
primers sequences used are shown in Supplementary
Table S4. The detailed description of the methods can
be found in Supplementary Data. The raw sequencing
data (ERP000266) was deposited at European
Nucleotide Archive (ENA) (http://www.ebi.ac.uk/ena/
index.html).
RESULTS
In order to assess the cargo capacity of PB, we have con-
structed a series of PB transposons with sizes of 28, 70 and
100 kb and tested their transposition in mouse ES cells. A
BAC containing the HPRT gene was used to construct
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these transposons. When introduced into Hprt-deficient
AB2.2 ES cells (23), these transposons can complement
Hprt deficiency, so that clones in which transposition
has occurred could be directly selected in hypoxanthine
amniopterin thymidine (HAT) medium. The HPRT
BAC was modified by insertion of PB ITRs up- and
down-stream of the HPRT locus to generate PB trans-
posons with 70 and 100 kb cargos (PB-HPRT-70 and
PB-HPRT-100). The 28 kb PB (PB-HPRT-28) was con-
structed by substituting the genomic regions of HPRT
from exons 3 to 9 with the corresponding part of the
HPRT cDNA within PB-HPRT-70 (Figure 1a). These
PB-BACs were further modified by insertion of a
PuroDtk cassette (17) immediately downstream of the
PB50ITR, so that direct BAC integrations could be
counter-selected. ES cell clones in which the HPRT gene
has been inserted by transposition should exclude the
PuroDtk cassette and will be resistant to FIAU (Figure 1b).
The Hprt-deficient AB2.2 ES cell line was transiently
transfected with one of two versions of the piggyBac
transposase (PBase); the mammalian codon optimized
version (mPBase) (19) or a hyperactive form (HyPBase)
(20). These PBase-expressing plasmids also contain a
puromycin selection cassette so that ES cells expressing
PBase could be enriched by a pulse puromycin selection
(24). As a negative control, a plasmid co-expressing
enhanced green fluorescent protein (eGFP) and the puro-
mycin resistant cassette was used. With pulse puromycin
selection enrichment, >50% of the ES cells were expected
to be expressing PBase, given the percentage of eGFP ex-
pressing cells obtained in the control (Supplementary
Figure S3). Three days after PBase transfection, the
BACs harboring different-sized PB transposons were
introduced by electroporation and HAT and FIAU con-
taining medium was used to select for ES cells with stable
integration of PB (Supplementary Figure S4). All three
PB-HPRT transposons gave rise to HAT and FIAU
double-resistant colonies that exceeded the number in
the non-PBase control (Figure 1c). Unexpectedly, the
number of double-resistant colonies did not vary greatly
with the size of the PB transposon. However, the number
of double-resistant colonies increased significantly when
HyPBase was supplied compared to mPBase. HAT and
FIAU resistant colonies can be generated by two
competing mechanisms: transposition or direct BAC inte-
gration with the loss of the PuroDtk cassette. The propor-
tion of direct BAC integration events was higher with the
70 and 100 kb PB transposons judged by the number of
HAT and FIAU double-resistant colonies in the
non-PBase control. The larger transposons are more
likely to have a higher background of HAT and FIAU
double-resistant colonies because the PuroDtk cassette is
located 20 kb from the 30-end of the HPRT gene whereas
the PuroDtk cassette in the 28 kb PB is only separated by
3 kb (Figure 1a). Genuine transposition can be distin-
guished from the direct BAC integration by analyzing se-
quences adjacent to the PB ITRs. If PBase-mediated
integration occurred, both ends of the PB ITRs should
be flanked by mouse genomic sequences together with
PB’s signature recognition site TTAA (8,22,25). If
random integration occurred, the original BAC vector
sequences adjacent to PB ITRs will be present. Illumina
sequencing technology was thus used to distinguish a large
number of genuine PB transposition events from direct
BAC integrations in a parallel fashion. HAT and FIAU
resistant colonies were pooled from each experimental
condition, and the genomic DNA was extracted and sub-
jected to paired-end sequencing to identify the PB50ITR—
genomic junctions (Supplementary Figure S2).
Transposition events were identified for all three trans-
posons when either mPBase or HyBase was used (Figure
1c and Supplementary Dataset S1). The number of trans-
position events decreased as the cargo size increased from
28 to 70 kb, however, the 70 and 100 kb PB showed a
similar number of events. The proportion of transposition
events among the HAT and FIAU double-resistant
colonies was lower with the 70 and 100-kb PB transposons
than the 28-kb PB transposon, reflecting the higher rate of
direct integration of BACs as seen in the HAT and FIAU
resistant colony number in the non-PBase control.
HyPBase-mediated transposition was approximately four
times that of mPBase for the larger transposons and seven
times for the 28-kb transposon. Albeit at lower efficiency,
wild-type PBase can mediate transposition with large
cargos, suggesting that the large-cargo capacity is an in-
trinsic property to piggyBac transposition, not acquired as
a result of modifications to PBase.
In a separate experiment, double-resistant colonies were
generated and analyzed individually to identify integration
sites using splinkerette PCR (22,26) (Supplementary
Table S5). For each transposon insertion analyzed, both
the PB50 and PB30ITR—host genome junction sequences
were contiguous in the mouse genome (Figure 2a).
Analysis of the copy number in these clones by Southern
blotting also revealed that almost all PB-mediated integra-
tions were single copy (Figure 2b). One of the major ad-
vantages of using transposition to deliver large genomic
DNA fragments is that cargo integrity is expected to
be maintained. To examine if this was also the case
with large-cargo transposition, we used a custom
high-resolution (average probe spacing of 130 bp) com-
parative genomic hybridization (CGH) array, covering
the entire human HPRT-containing BAC excluding the
vector backbone. Four independent clones with 70 kb
(Cd8 and Ch2) and 100 kb (Dc7 and Dc11) PB insertions
were assessed. The regions of copy number gain in all the
clones precisely matched the regions of the BAC flanked
by the PB ITRs (Supplementary Figure S5). Within these
regions, the human DNA sequences were continuous and
did not contain any detectable change (Figure 2c). Thus,
the large cargos mobilized as PB transposons remained
intact in all cases.
We have demonstrated that giant piggyBac transposons
can efficiently deliver intact genomic cargos to the host
genome. With the human HPRT locus as the cargo, we
were able to use HAT selection to enrich ES cell clones
with the entire locus integrated. In order to demonstrate
that giant piggyBac vectors can mediate transposition of
any genomic cargo without such a stringent selection, we
investigated the use of a small selection cassette instead of
HPRT. The PB-HPRT-100 BAC was electroporated into
AB2.2 cells following HyPBase lipofection as described
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previously and the cells were selected in either G418 selec-
tion or G418+FIAU dual selection. Individual colonies
from these two selection schemes were subjected to
splinkerrette PCR analysis, which identified transposition
events from both selection schemes. The proportion of
transposition events was five times greater under
G418+FIAU dual selection than using G418 selection
alone (Table 1). The proportion of genuine transposition
events obtained with the 100-kb PB transposon using
G418+FIAU selection (40%; Table 1) was comparable
to that previously obtained using HAT+FIAU dual se-
lection (29%; Figure 1c). This data confirms that giant
piggyBac vectors can be efficiently transposed without
strong positive selection for an intact cargo.
To further demonstrate the applicability of the giant
piggyBac system, we constructed another PB-BAC
vector, PB-FAH-62.5, a 62.5-kb PB transposon harboring
the entire human FAH locus (34-kb coding region) and its
surrounding genome sequences (Figure 3a). A positive en-
richment strategy for transposition events was also
assessed in conjunction with selection for PB integration.
A CMV promoter was cloned at one end of the trans-
poson and the puromycin coding sequence was cloned at
the other, 62.5 kb away. Upon PB excision, the CMV
promoter and puromycin coding sequences are brought
together and this can provide transient puromycin expres-
sion in the host cells (Figure 3a). The PB-FAH-62.5 BAC
was electroporated into ES cells following HyPBase
lipofection as described previously. In separate experi-
ments, the PB-FAH-62.5 BAC was introduced into the
ES cells by co-lipofection with the HyPBase plasmid.
The transfected cells were either selected directly using
G418 or transiently selected using puromycin for 48 h
prior to G418 selection. Individual drug-resistant
colonies were picked and genuine transposition events
were identified by splinkerette PCR from all conditions.
Co-lipofection of the BAC with the HyPBase plasmid
resulted in a 3-fold higher rate of transposition events
compared with BAC electroporation after HyPBase
lipofection (Figure 3b). Transient puromycin selection
for PB excision from the donor BAC resulted in slight
enrichment in the rate of transposition, although this
method was less efficient than using PuroDtk-based
negative selection (Table 1). Taken together, giant
piggyBac vectors can mediate stable delivery of the
genomic cargo into the host genome and the use of a
Figure 1. PiggyBac-mediated large-cargo transposition in mouse ES cells. (a) Giant HPRT-PiggyBac constructs modified from the same BAC.
(b) A scheme of competing genomic integration pathways. PBase can mediate precise excision of the giant PB from the BAC and insert it into the ES
cell genome, generating cells that are resistant both to HAT and FIAU. If physical breakage of the BAC occurs and the PB ITRs are separated and
random integration of the BAC can occur together with the PuroDtk cassette. If the HPRT gene on the BAC is intact, the cells will be HAT resistant
but sensitive to FIAU. (c) Transposition efficiency of different sized PB transposons and versions of the PBase. The number of transposition events
was determined using massively parallel sequencing from pooled HAT and FIAU resistant clones. Asterisks indicate percentage of transposition
events as a fraction of HAT and FIAU double-resistant colonies. The transposition events are assumed to be one per cell.
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linked positive and negative selection strategy provides the
most efficient mean to isolate genuine transposition
events.
We next investigated if large-cargo transposons could
be mobilized from the host genome. ES cell lines with
28 kb (Bf6), 70 kb (Cd8 and Ch2) or 100 kb (Dc7 and
Dc11) PB transposons were transiently transfected with
HyPBase and enriched for expression with a pulse puro-
mycin selection. Following a period of culture to allow for
the decay of HPRT mRNA and protein products, the cells
were plated at low density and selected in 6-thioguanine
(6-TG) for cells which have excised the PB-HPRT trans-
poson from their genome. PB excision was observed for all
clones tested with efficiencies ranging from 0.1% to 0.6%
of the total number of cells plated (Figure 4a). A few 6-TG
resistant clones were observed in controls and their
numbers varied between different cell lines. This could
be due to loss of heterozygosity events of the autosomal
PB-HPRT loci, resulting in a small number of ES cells
without the transposon.
To confirm the fidelity of PB excision, four
6-TG-resistant colonies derived from each of the five
parental PB-containing clones were examined by
genomic PCR using transposon–host-specific primer sets
for each integration site, and none exhibited the PB
ITR-host genomic junctions (Figure 4b). PB does not
normally leave a footprint upon excision. We therefore
sequenced the transposon excision sites in all of the
6-TG-resistant clones to check for their intactness.
Precise excision was observed in all clones derived from
the three donor sites (Cd8, Ch2 and Dc11). However,
one out of four 6-TG-resistant clones derived from
the Dc7 clone showed a micro-deletion (Figure 4c).
Figure 2. Large cargos delivered by giant PB transposons are intact. (a) Precise integration of giant PB transposons at the expected TTAA site. The
chromosomal coordinates of the first T corresponding to the PB recognition site TTAA are shown (NCBI m37). The shaded sequences represent the
ends of the PB ITRs. (b) Southern blot illustrating the copy number of the PB mediated largo-cargo integrations using the PB50ITR as the detection
probe. (c) Regional CGH analysis showing the gain of an extra copy of the human HPRT gene delivered by PB transposition. The red line was
calculated as the running median of the Log2 value of each CGH probe to aid the visualization.
Table 1. Transposition enrichment of PB-HPRT-100 using different
selection schemes
PB-HPRT-100:
selection
HyBase eGFP
Colonies
number
Colonies
analyzed
Transposition
events (%)a
Colonies
number
G418 75 37 3 (8%) 31
G418+FIAU 30 10 4 (40%) 10
‘Colony analyzed’: the number of colonies analyzed with splinkerrette
PCR method for the determination of the PB ITR to genomic junction
sequence.
aPercentage of transposition events is a fraction of colonies analyzed.
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Figure 4. PBase-mediated excision of giant PB transposons from the ES cell genome. (a) Genomic excision efficiency of five ES cell clones containing
giant PB transposons with different cargo sizes following transfection with either HyPBase or an eGFP (control). (b) Molecular analysis of individual
6-TG-resistant colonies to evaluate fidelity of excision events. Excision of PB eliminates the PB-host junction fragment amplified in the parental lines.
(c) Analysis of PB excision identified one clone with a micro-deletion (clone Dc7) following the excision of a 100-kb PB transposon. ‘n’ represents the
number of 6-TG-resistant colonies with the shown sequence traces of the excision site.
Figure 3. Stable integration of a PB transposon harboring the human FAH locus. (a) Schematic representation of the PB-FAH-62.5 construct and
the selection strategy used for enriching genuine transposition events. (b) Transposition efficiency of PB-FAH-62.5 using different transfection
methods and selection schemes. ‘Colonies analyzed’: the number of colonies analyzed by splinkerrette PCR for the determination of the PB ITR
to genomic junction sequence. Asterisk indicates percentage of transposition events as a fraction of colonies analyzed.
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Micro-deletions upon PB excision have been reported pre-
viously with PB transposons harboring <10 kb cargos
(25), suggesting that this low frequency of imprecise
excision is not due to the size of the cargo.
DISCUSSION
In this study, we have demonstrated that giant piggyBac
transposons of up to 100 kb can be mobilized from ex-
ogenous BAC vectors and endogenous genomic loci in
mouse ES cells. Transposition achieves a stable but pre-
cisely revertible genomic insertion. Importantly, large
DNA cargos remain intact during transposition and the
copy number of the delivery is predominantly one.
In the vector-to-chromosome transposition assay, the
efficiency of transposition dropped as the cargo size
increased (Figure 1c). This could be caused by the lack
of integrity of the circular BAC during preparation and
electroporation into cells. Naked BAC DNA ends may
stimulate direct BAC integration, thus posing a direct
competition with PB-mediated transposition. In
addition, BAC breakage between PB ITRs prevents trans-
position by destruction of a suitable PB transposon struc-
ture. The chance of a break occurring between the PB
ITRs increases with the distance between them. In the
chromosomal transposition assay, the frequency of
excision appeared to be less dependent on the size of
the transposon than the integration site. This supports
the view that one of the major factors influencing
vector-to-chromosome transposition is the continuity of
the BAC DNA between the PBITRs, rather than
inherent limits in the transposition reaction per se.
Therefore, 100 kb is not likely to be the upper limit for
the cargo capacity of piggyBac.
In the system described here, transposition events can
be further enriched by negative selection using FIAU,
because transposition uncouples the PB transposon from
a negatively selectable puroDtk cassette on the BAC
backbone. It follows that the tighter the linkage between
the positive selection marker in the transposon and the
negative selection cassette, the greater the degree of en-
richment for transposition events. The tight linkage in
the 100-kb transposon allowed us to record a 30% trans-
position rate after positive–negative selection (Figure 1c).
Similar rates were also achieved using a small positive se-
lection marker, such as a neomycin resistant cassette
(Table 1). Taken together, the tight positive–negative se-
lection scheme is very useful and applicable to any
genomic cargo design, and can efficiently enrich for trans-
position by selecting against direct integration of the
BAC DNA.
In our excision experiment, 6-TG selection was
employed to analyze the giant piggyBac excision frequency
and footprints. 6-TG selects against the re-integration
events of the PB-HPRT transposons, thus we were not
able to determine the re-integration rate. Further experi-
mentation is required to analyze re-integration.
We have demonstrated that giant PB transposons ef-
fectively deliver intact large genomic DNA fragments
with a controllable copy number. This is useful in many
genetic applications such as BAC transgenesis and genetic
complementation. Another DNA transposon, Tol2, has
also recently been shown to deliver a 70-kb genomic
DNA for transgenesis (27). The additional ability of
piggyBac to cleanly excise large genomic DNA fragments
provides a valuable genome engineering technology for
creating in vitro and in vivo gains and losses of large
genomic regions.
PB-mediated integration of large genomic fragments
can provide permanent complementation with prolonged
and physiologically regulated gene expression. It also
avoids the complications of viral vectors, which can
induce host-immune responses and tumorigenesis.
Although PB integration sites can not currently be
pre-defined, specific integration sites of PB can be
screened to identify permissive locations that are not
likely to affect normal function for therapeutic gene
delivery. The development of giant PB transposons will
be valuable for therapeutic gene delivery of large
genomic sequences in patient-specific-induced pluripotent
stem (iPS) cells or adult stem cells to combat a range of
human genetic diseases.
Giant PB transposons are comparatively simple to con-
struct. In principle, a genome-wide resource of PB-BACs
could be generated using recombineering technology (28).
Such a resource can be used in genetic screens and in com-
plementation studies. Transient expression of PBase to
mediate giant PB transposition does not require prior
genome modification, thus giant PB libraries can be used
in most cell types and organisms.
Taken together, the work presented here provides a
framework for using piggyBac to mobilize large genomic
DNA fragments. This will open the door to a wide range
of future applications in genetics and genomic research as
well as clinical medicine, which have been difficult to
conduct previously with other tools.
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